KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Common Equity (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Common Equity data on record, last reported at $618.0 million in Q3 2025.

  • For Q3 2025, Common Equity fell 6.72% year-over-year to $618.0 million; the TTM value through Sep 2025 reached $618.0 million, down 6.72%, while the annual FY2024 figure was $588.4 million, 52.15% up from the prior year.
  • Common Equity reached $618.0 million in Q3 2025 per IONS's latest filing, down from $631.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $771.7 million in Q4 2021 and bottomed at $263.7 million in Q2 2024.
  • Average Common Equity over 5 years is $537.9 million, with a median of $582.7 million recorded in 2021.
  • Peak YoY movement for Common Equity: tumbled 65.11% in 2021, then soared 139.56% in 2025.
  • A 5-year view of Common Equity shows it stood at $771.7 million in 2021, then dropped by 25.77% to $572.9 million in 2022, then plummeted by 32.5% to $386.7 million in 2023, then soared by 52.15% to $588.4 million in 2024, then grew by 5.03% to $618.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $618.0 million in Q3 2025, $631.7 million in Q2 2025, and $475.7 million in Q1 2025.